FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:499-501 August 14, 1997 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Katz, M. H. PubMed Citation

To the Editor: Katz and Gerberding (April 10 issue)¹ raise questions about public health policy related to the costs of antiretroviral therapy given immediately after an exposure to the human immunodeficiency virus (HIV) to prevent seroconversion in persons at high risk for HIV infection. Using their data and the techniques of decision analysis, we examined the cost effectiveness of prophylaxis against HIV.

We compared no prophylaxis with prophylaxis with zidovudine; zidovudine and lamivudine; and zidovudine, lamivudine, and indinavir — all given for four weeks at average wholesale costs of $260, $469, and $931, respectively. The cost of initial and follow-up . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Lurie, P., Miller, S., Hecht, F., Chesney, M., Lo, B. (1998). Postexposure Prophylaxis After Nonoccupational HIV Exposure: Clinical, Ethical, and Policy Considerations. JAMA 280: 1769-1773 [Abstract] [Full Text]